BioPharma Resources

Drug Trial Radar · NCT04559204

Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4

A Multi-centered, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of Combined Immunization of 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) and Quadrivalent Inactivated Influenza Vaccine (IIV4)

Last checked: Nov 19, 2026Latest source record: Aug 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,224 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,224

Actual

Start

Sep 11, 2020

Primary completion

Nov 26, 2020

Study completion Oct 9, 2021

Sponsor

Sponsor type
Industry
Collaborators
Center for Disease Control and Prevention, Fujian; Chengdu Institute of Biological Products Co.,Ltd.; Changchun Institute of Biological Products Co., Ltd.; National Institutes for Food and Drug Control, China; Guizhou Center for Disease Control and Prevention; Hunan Provincial Center for Disease Control and Prevention; Peking University
First posted
Sep 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 3 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Subjects will be recruited and divided into 3 groups: 1. Experimental Group (408 subjects): combined immunization of PPV23 and IIV4; 2. Control Group A (408 subjects): IIV4 only; 3. Control Group B (408 subjects): PPV23 only; All blood samples will be collected before and one month after vaccinatioin. The immunogenicity and safety of both experimental and control groups will be compared and the data be analyzed.

Conditions

  • Influenza, Human
  • Pneumonia, Pneumococcal

Interventions

  • IIV4 and PPV23Biological

    imultaneously immunization of 23-valent pneumococcal polysaccharide vaccine (PPV23) and quadrivalent inactivated influenza vaccine (IIV4)

  • IIV4Biological

    administrated with IIV4 only

  • PPV23Biological

    administrated with PPV23 only

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Seroconversion rate (IIV4)Time frame: Baseline (before vaccination) results
  2. Seroconversion rate (IIV4)Time frame: Results obtained 1 month after vaccination
  3. Seroconversion rate (PPV23)Time frame: Baseline (before vaccination) results
  4. Seroconversion rate (PPV23)Time frame: Results obtained 1 month after vaccination
  5. Geometric Mean Concentration (GMC) (IIV4)Time frame: Baseline (before vaccination) results
  6. Geometric Mean Concentration (GMC) (IIV4)Time frame: Results obtained 1 month after vaccination
  7. Geometric Mean Concentration (GMC) (PPV23)Time frame: Baseline (before vaccination) results
  8. Geometric Mean Concentration (GMC) (PPV23)Time frame: Results obtained 1 month after vaccination

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Liucheng Community Health Services Center

    Quanzhou, Fujian, China

  • Luodong County Health Center

    Quanzhou, Fujian, China

  • Qingzhen Center for Disease Control and Prevention

    Qingzhen, Guizhou, China

  • Qidong County Center for Disease Control and Prevention

    Hongqiao, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.